Proteon Therapeutics Inc (NASDAQ:PRTO) has been assigned a consensus recommendation of “Hold” from the six brokerages that are currently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $2.50.
Separately, Zacks Investment Research upgraded Proteon Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 14th.
Shares of PRTO stock traded up $0.02 during midday trading on Thursday, reaching $0.29. 63,400 shares of the stock were exchanged, compared to its average volume of 753,350. Proteon Therapeutics has a 1 year low of $0.22 and a 1 year high of $3.94. The company’s 50 day moving average is $0.26 and its two-hundred day moving average is $0.35. The firm has a market cap of $5.64 million, a PE ratio of -0.25 and a beta of 0.43.
An institutional investor recently raised its position in Proteon Therapeutics stock. Wedbush Securities Inc. grew its position in shares of Proteon Therapeutics Inc (NASDAQ:PRTO) by 60.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 166,472 shares of the biopharmaceutical company’s stock after buying an additional 62,472 shares during the quarter. Wedbush Securities Inc. owned 0.85% of Proteon Therapeutics worth $43,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 24.38% of the stock is owned by institutional investors and hedge funds.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes.
Featured Story: Why is the LIBOR significant?
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.